Leukemia patients see good results from Gleevec challengers

Drugs expected to help certain leukemia patients who saw relapses while taking Gleevec apparently are seeing cancer remission success rates in new clinical trials. About 86% of trial participants on Bristol-Myers Squibb's drug demonstrated a "hematologic" remission after up to nine months on the drug while Novartis, maker of Gleevec, has tested a successor that also has produced fewer side effects than the original.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY